Clinical

Dataset Information

0

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer


ABSTRACT: Colorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H cannot benefit from 5-fluorouracil (5-FU) adjuvant chemotherapy. Once patients have distant metastases, they are not sensitive to traditional palliative chemotherapy, and the prognosis is significantly worse than that of mismatch repair-proficient (pMMR)/microsatellite stability (MSS). A phase II clinical study of anti-PD-1 immunotherapy based on mismatch repair (MMR) status published in 《N Engl J Med》 showed that the objective response rate (ORR) of advanced colorectal cancer patients with dMMR received anti-PD-1 is 40%, and a longer response time can be obtained compared to conventional chemotherapy. Anti-PD-1 neoadjuvant therapy has proven to be safe and feasible in lung cancer, bladder cancer and malignant melanoma, and can achieve more than 40% of major pathological response. However, there are no reports of anti-PD-1 neoadjuvant therapy for the dMMR/MSI-H colorectal cancer. Therefore, the aim of this study was to find the best multidisciplinary treatment for resectable colorectal cancer patient with the dMMR/MSI-H phenotype and to explore whether cyclooxygenase (COX) inhibitors combined with anti-PD-1 monoclonal antibody (mAb) could further improve efficacy.

DISEASE(S): Microsatellite Instability,Mismatch Repair-deficient (dmmr),Colorectal Cancer,Colorectal Neoplasms,Neoadjuvant Therapy,Microsatellite Instability-high (msi-h)

PROVIDER: 2303741 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-04-07 | GSE149206 | GEO
| 2729957 | ecrin-mdr-crc
2023-06-01 | GSE211221 | GEO
2023-06-01 | GSE210018 | GEO
2011-03-01 | E-GEOD-24514 | biostudies-arrayexpress
2011-03-01 | GSE24514 | GEO
2021-08-30 | GSE175744 | GEO
| 2385325 | ecrin-mdr-crc
2023-05-11 | GSE205506 | GEO
| 2346468 | ecrin-mdr-crc